Roche secures worldwide rights to Zymeworks' DLL3 trispecific ZW209 for SCLC and neuroendocrine tumors. Read the full deal ...

Pathos AI and Bristol Myers Squibb launch an Alzheimer's AI drug development collaboration, including a USD 55m Tempus data ...

Merck and Moderna's intismeran with Keytruda cut melanoma recurrence or death risk by 42% in the Phase III INTerpath-001 trial. Read the full details now.

Discover how SERPINA3 binds SIRPα as a soluble ligand to suppress inflammatory immune cells in preclinical studies. Read the ...

Notre Dame researchers identify a TfR1 dimer that rises during ferroptosis, detectable in tissue and blood. Read the full study findings to learn more now.

Stanford's AI digital twin predicts aspirin plus lansoprazole could delay labor about 15 times longer than aspirin alone.

Get the full details on Vyglxia now. FDA accepts Biohaven's resubmitted troriluzole NDA for spinocerebellar ataxia (SCA), ...

Columbia researchers reveal how PARG inhibitors trap DNA-repair proteins to kill cancer cells, pointing to a possible ...

Menarini's Stemline licenses GIM-621, a first-in-class oral immuno-oncology agent from Georgiamune, in a deal worth up to $1.1B. Read the full story now.

Astellas licenses AI Proteins' de novo miniprotein platform in a deal worth up to $400M. Read the details of this AI drug ...

Olorofim meets its non-inferiority goal against AmBisome in the Phase III OASIS trial for invasive aspergillosis. Read full ...

Muna Therapeutics' oral TREM2 modulator MNA-001 showed no serious adverse events in Phase I. Read how the Phase II ...